JP2023526045A5 - - Google Patents
Info
- Publication number
- JP2023526045A5 JP2023526045A5 JP2022568765A JP2022568765A JP2023526045A5 JP 2023526045 A5 JP2023526045 A5 JP 2023526045A5 JP 2022568765 A JP2022568765 A JP 2022568765A JP 2022568765 A JP2022568765 A JP 2022568765A JP 2023526045 A5 JP2023526045 A5 JP 2023526045A5
- Authority
- JP
- Japan
- Prior art keywords
- hcv
- nucleic acid
- variable domain
- composition
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020901506A AU2020901506A0 (en) | 2020-05-11 | Compositions and their prophylactic or therapeutic use | |
| AU2020901506 | 2020-05-11 | ||
| PCT/AU2021/050437 WO2021226664A1 (en) | 2020-05-11 | 2021-05-11 | A hepatitis c nucleic acid vaccine comprising a variable domain deleted e2 polypeptide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526045A JP2023526045A (ja) | 2023-06-20 |
| JP2023526045A5 true JP2023526045A5 (https=) | 2024-05-20 |
Family
ID=78525848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022568765A Pending JP2023526045A (ja) | 2020-05-11 | 2021-05-11 | 可変ドメイン欠失ｅ２ポリペプチドを含むｃ型肝炎核酸ワクチン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230181726A1 (https=) |
| EP (1) | EP4149541A4 (https=) |
| JP (1) | JP2023526045A (https=) |
| CN (1) | CN115843270A (https=) |
| AU (1) | AU2021270053A1 (https=) |
| BR (1) | BR112022023101A2 (https=) |
| CA (1) | CA3178547A1 (https=) |
| WO (1) | WO2021226664A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12576041B1 (en) * | 2021-07-14 | 2026-03-17 | Dean Nakamura | Transient expression of biologic materials |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7602800A (en) * | 1999-09-23 | 2001-04-24 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof |
| EP2061805B1 (en) * | 2006-08-25 | 2020-02-12 | Macfarlane Burnet Institute for Medical Research and Public Health Limited | Recombinant hcv e2 glycoprotein |
| CN103354748B (zh) * | 2010-08-04 | 2016-09-28 | 麦克法兰博尼特医学健康研究公司 | 修饰的丙型肝炎病毒蛋白 |
| WO2016141201A2 (en) * | 2015-03-04 | 2016-09-09 | University Of Maryland | Rational vaccine design for hepatitis c virus |
| CN110049993A (zh) * | 2016-09-29 | 2019-07-23 | 麦克法兰布奈特医疗研究与公共健康研究所有限公司 | 组装的糖蛋白 |
-
2021
- 2021-05-11 US US17/924,646 patent/US20230181726A1/en active Pending
- 2021-05-11 CN CN202180043193.7A patent/CN115843270A/zh active Pending
- 2021-05-11 WO PCT/AU2021/050437 patent/WO2021226664A1/en not_active Ceased
- 2021-05-11 JP JP2022568765A patent/JP2023526045A/ja active Pending
- 2021-05-11 CA CA3178547A patent/CA3178547A1/en active Pending
- 2021-05-11 AU AU2021270053A patent/AU2021270053A1/en active Pending
- 2021-05-11 BR BR112022023101A patent/BR112022023101A2/pt unknown
- 2021-05-11 EP EP21804220.8A patent/EP4149541A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7663622B2 (ja) | 広域スペクトルな抗インフルエンザワクチン免疫原及びその使用 | |
| Christensen et al. | Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8+ T-cell memory | |
| JP2022160401A5 (https=) | ||
| JP2025084808A (ja) | エプスタイン－バーウイルスワクチン | |
| JP2023518340A5 (https=) | ||
| JP2017515508A5 (https=) | ||
| WO2022071513A1 (ja) | ＳＡＲＳ－ＣｏＶ－２に対する改良型ＤＮＡワクチン | |
| JP2023522154A5 (https=) | ||
| JP2023527083A5 (https=) | ||
| JP2023526045A5 (https=) | ||
| JP2023515806A5 (https=) | ||
| WO2019163781A1 (ja) | エンテロウイルスワクチン | |
| AU2016313660A1 (en) | Polypeptide carrier for presenting target polypeptide and uses thereof | |
| CA3076263C (en) | Synthetic hemagglutinin as universal vaccine against infection by type b influenza viruses (ibv) | |
| JP5901084B2 (ja) | ペプチドアジュバント | |
| US20160279229A9 (en) | Viral Vaccine Vectors | |
| CN110382518B (zh) | 用于血清型a型口蹄疫病毒的嵌合疫苗 | |
| US20160228531A1 (en) | Treatment of hepatitis d virus infections by redirection of t cells | |
| JP2022513438A5 (https=) | ||
| JP2025529128A (ja) | カスパーゼ活性化及び動員ドメイン（ａｓｃ）を有するアポトーシス関連スペック様タンパク質を標的化する組成物及び使用方法 | |
| JP2024523329A5 (https=) | ||
| Robertson et al. | International Nonproprietary Names (INN) for novel vaccine substances: a matter of safety | |
| CN113185586A (zh) | SARS-CoV-2编码蛋白来源的T细胞表位多肽及其应用 | |
| CN113227360A (zh) | 具有新型流感病毒来源的血凝素蛋白基因的DIs株来源的重组牛痘病毒 | |
| Chattopadhyay et al. | Nasal Vaccine: A Special Prominence on SARS-CoV-2 |